BIOGEN INC (BIIB)
US09062X1037 - Common Stock
ChartMill assigns a Buy % Consensus number of 79% to BIIB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 310.32. This target is 62.22% above the current price.
BIIB was analyzed by 42 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about BIIB.
In the previous month the buy percentage consensus was at a similar level.
BIIB was analyzed by 42 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-17 | UBS | Maintains | Neutral -> Neutral |
| 2024-04-17 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-04-12 | B of A Securities | Maintains | Neutral -> Neutral |
| 2024-04-11 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-04-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-03-25 | Truist Securities | Reiterate | Buy -> Buy |
| 2024-03-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-02-22 | Mizuho | Maintains | Buy -> Buy |
| 2024-02-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-02-20 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-02-16 | UBS | Maintains | Neutral -> Neutral |
| 2024-02-14 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-02-14 | Needham | Maintains | Buy -> Buy |
| 2024-02-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-02-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-14 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-02-14 | Baird | Maintains | Outperform -> Outperform |
| 2024-02-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-02-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-13 | Needham | Reiterate | Buy -> Buy |
| 2024-01-30 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-01-25 | UBS | Downgrade | Buy -> Neutral |
| 2024-01-24 | UBS | Downgrade | Buy -> Neutral |
| 2023-12-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-12-18 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-12-14 | Stifel | Maintains | Buy -> Buy |
| 2023-12-07 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2023-11-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-11-09 | BMO Capital | Maintains | Outperform -> Outperform |
| 2023-11-09 | RBC Capital | Maintains | Outperform -> Outperform |